Discovering global opportunities to deliver life-changing cures.
Biosion's Partner Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052Release time:2025-06-26 11:05:00Nanjing, China, Newark, U.S.A June. 23, 2025-Biosion, a global, clinical-stage biotechnology company, announced that its partner, Aclaris Therapeutics, Inc.
Newark, DE, U.S. and Nanjing, China, Apr. 27, 2025-Biosion, a global clinical-stage biotechnology company, announced that its partner, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) applicat
NANJING, China and NEWARK, Del., April 11, 2025-Biosion, Inc. , a global, clinical-stage biotechnology company, today announced that preclinical data for BSI-721, a novel antibody-drug conjugate (ADC) targeting CDH17, will be presented at the upcoming American Association for Cancer Research (AAC
New funding will strengthen Biosion’s “In Global For Global” positioning by accelerating its clinical pipeline and expanding its global biologics development teams
HAMPTON, N.J., November 12, 2021 — Celldex Therapeutics, Inc. today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform. These data were presented in a poster ses
Newark, DE, Nanjing CN – Dec 10, 2020. Biosion Inc. (“Biosion”) today announced completion of ¥200 Million RMB (~$30 Million USD) of financing to transition Biosion into a clinical stage company within twelve months. The financing was led by Lapam Capital, joined by Kaiyuan Capital, Oceanpine Health